activepal tm triaxial accelerometer (PAL Technologies Ltd)
Structured Review

Activepal Tm Triaxial Accelerometer, supplied by PAL Technologies Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/activepal+triaxial+accelerometer/activpal+accelerometer/pmc11706455-424-12-16
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Supervised pulmonary tele-rehabilitation and individualized home-based pulmonary rehabilitation for patients with COPD, unable to participate in center-based programs. The protocol for a multicenter randomized controlled trial - the REPORT study"
Article Title: Supervised pulmonary tele-rehabilitation and individualized home-based pulmonary rehabilitation for patients with COPD, unable to participate in center-based programs. The protocol for a multicenter randomized controlled trial - the REPORT study
Journal: PLOS ONE
doi: 10.1371/journal.pone.0312742
Figure Legend Snippet: Outcomes and flowchart of study measurements.
Techniques Used: Activity Assay, Battery
Related Articles
other:Article Title: Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe COPD: a randomised multicentre trial Article Snippet: The PAL was measured with Activity Assay:Article Title: 12-months follow-up of pulmonary tele-rehabilitation versus standard pulmonary rehabilitation: A multicentre randomised clinical trial in patients with severe COPD. Article Snippet: Between March 2016 and October 2017, we randomised 134 patients with severe COPD from 8 hospitals in the Capital Region of Denmark to participate in either standardised, outpatient pulmonary rehabilitation (control group) or on-line, supervised and home-based tele-rehabilitation (intervention group).. We found no difference between the groups in the primary outcome: six minutes walking distance (6MWD) after completion of the programme.. The current study presents results from the 12-month follow-up with assessment of the 6MWD and analyses of hospitalisation and mortality. |